Reply to: "Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients".

Yael Renert-Yuval Emma Guttman-Yassky

Published in: Allergy (2022)

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
atopic dermatitis
patient reported